Dimensional Fund Advisors LP Trims Position in Vera Therapeutics, Inc. (NASDAQ:VERA)

Dimensional Fund Advisors LP decreased its holdings in shares of Vera Therapeutics, Inc. (NASDAQ:VERA) by 10.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 15,832 shares of the company’s stock after selling 1,900 shares during the quarter. Dimensional Fund Advisors LP’s holdings in Vera Therapeutics were worth $670,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Marshall Wace LLP lifted its position in Vera Therapeutics by 43.4% in the 4th quarter. Marshall Wace LLP now owns 837,146 shares of the company’s stock worth $35,403,000 after buying an additional 253,421 shares during the last quarter. Barclays PLC increased its stake in shares of Vera Therapeutics by 16.1% during the fourth quarter. Barclays PLC now owns 99,148 shares of the company’s stock valued at $4,192,000 after buying an additional 13,753 shares during the period. Summit Investment Advisors Inc. increased its stake in shares of Vera Therapeutics by 16.0% during the fourth quarter. Summit Investment Advisors Inc. now owns 4,639 shares of the company’s stock valued at $196,000 after buying an additional 639 shares during the period. Optimize Financial Inc purchased a new stake in Vera Therapeutics in the fourth quarter worth $249,000. Finally, Raymond James Financial Inc. purchased a new stake in Vera Therapeutics in the fourth quarter worth $2,948,000. Hedge funds and other institutional investors own 99.21% of the company’s stock.

Vera Therapeutics Stock Down 0.4%

Shares of VERA stock opened at $21.25 on Friday. Vera Therapeutics, Inc. has a 1-year low of $18.53 and a 1-year high of $51.61. The stock’s fifty day moving average price is $23.49 and its 200 day moving average price is $34.01. The company has a debt-to-equity ratio of 0.17, a current ratio of 13.76 and a quick ratio of 13.76. The company has a market cap of $1.35 billion, a price-to-earnings ratio of -8.14 and a beta of 1.28.

Vera Therapeutics (NASDAQ:VERA) last announced its earnings results on Thursday, May 8th. The company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.06). During the same period in the previous year, the firm posted ($0.56) earnings per share. On average, research analysts expect that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current fiscal year.

Analysts Set New Price Targets

VERA has been the topic of several analyst reports. Wedbush dropped their target price on Vera Therapeutics from $34.00 to $26.00 and set a “neutral” rating on the stock in a report on Wednesday, May 7th. Cantor Fitzgerald lowered their price target on Vera Therapeutics from $107.00 to $100.00 and set an “overweight” rating on the stock in a report on Wednesday, May 7th. Wolfe Research started coverage on Vera Therapeutics in a report on Tuesday, February 4th. They issued an “outperform” rating and a $49.00 target price on the stock. JPMorgan Chase & Co. reduced their price target on Vera Therapeutics from $77.00 to $71.00 and set an “overweight” rating for the company in a research report on Tuesday, March 4th. Finally, The Goldman Sachs Group initiated coverage on Vera Therapeutics in a research report on Tuesday, January 28th. They set a “buy” rating and a $58.00 target price for the company. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $63.33.

Vera Therapeutics Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.